The Role of STAT3 in Non-Small Cell Lung Cancer

The Role of STAT3 in Non-Small Cell Lung Cancer

Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has been demonstrated in 22%~65% of non-small cell lung cancers (NSCLC). STAT3 activation is mediated by receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and MET, cytokine receptors, s...

Full description

Bibliographic Details
Main Authors:	Daijiro Harada, Nagio Takigawa, Katsuyuki Kiura
Format:	Article
Language:	English
Published:	MDPI AG 2014-03-01
Series:	Cancers
Subjects:	signal transducer and activator of transcription 3 Janus kinase 2 epidermal growth factor receptor non-small cell lung cancer drug resistance
Online Access:	http://www.mdpi.com/2072-6694/6/2/708

Similar Items

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
by: Charles J. Malemud
Published: (2010-05-01)

STAT3: Versatile Functions in Non-Small Cell Lung Cancer
by: Julian Mohrherr, et al.
Published: (2020-04-01)

Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism
by: Yuchen Nan, et al.
Published: (2017-12-01)

Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
by: Paula Montero, et al.
Published: (2021-06-01)

Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages
by: Xin Zhang, et al.
Published: (2017-05-01)

Janus Kinase-Signal Transducer and Activator of Transcription in target therapy of cancer
by: Lior Shoev, et al.
Published: (2019-09-01)

Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy
by: Sankhadip Bose, et al.
Published: (2020-06-01)

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
by: Iain B. McInnes, et al.
Published: (2019-08-01)

Basics of Janus kinases: a review
by: Hanan R Nada, et al.
Published: (2020-01-01)

The two faces of Janus kinases and their respective STATs in mammary gland development and cancer
by: Kay-Uwe Wagner, et al.
Published: (2011-01-01)

Isolinderalactone Induces Cell Death via Mitochondrial Superoxide- and STAT3-Mediated Pathways in Human Ovarian Cancer Cells
by: Shakya Rajina, et al.
Published: (2020-10-01)

Activity of JAK/STAT and NF-kB in patients with axial spondyloarthritis
by: Jerzy Świerkot, et al.
Published: (2015-12-01)

“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
by: Emira Bousoik, et al.
Published: (2018-07-01)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
by: Seo Yun Moon, et al.
Published: (2021-08-01)

Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models
by: Sun Young Moon, et al.
Published: (2021-05-01)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
by: Satoshi Kubo, et al.
Published: (2018-06-01)

Clinicopathologic and prognostic significance of VEGF, JAK2 and STAT3 in patients with nasopharyngeal carcinoma
by: Jin-Zhang Cheng, et al.
Published: (2018-08-01)

The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension
by: Inés Roger, et al.
Published: (2021-05-01)

Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer
by: Sebastian Zundler, et al.
Published: (2016-02-01)

Inhibitory effects of the JAK inhibitor CP690,550 on human CD4<sup>+ </sup>T lymphocyte cytokine production
by: Yamasaki Satoshi, et al.
Published: (2011-08-01)

Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function
by: Aisling O’Brien, et al.
Published: (2021-06-01)

STATs family expression in non-small cell lung cancer tissue and their potential target genes
by: Ze-Jun Lu, et al.
Published: (2017-06-01)

Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors
by: Wenqiu ZHANG, et al.
Published: (2017-10-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
by: Emma-Anne Karlsen, et al.
Published: (2021-05-01)

Delayed administration of suramin attenuates peritoneal fibrosis in rats
by: Chongxiang Xiong, et al.
Published: (2019-11-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
by: Daijiro Harada, et al.
Published: (2021-03-01)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
by: Fang Wang, et al.
Published: (2019-03-01)

Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from <i>Centipeda minima</i>
by: Byoung Ha Kim, et al.
Published: (2020-06-01)

Fructose 1,6-diphosphate alleviates myocardial ischemia reperfusion injury in rats through JAK2/STAT3 pathway
by: Ju-Fei Wang, et al.
Published: (2018-01-01)

Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma
by: Lidia García-Colmenero, et al.
Published: (2020-12-01)

<i>Drosophila</i> Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis
by: Sunny Trivedi, et al.
Published: (2018-12-01)

Current perspectives on the JAK/STAT signaling pathway and its activating factors in liver fibrosis
by: PAN Jin
Published: (2013-05-01)

Ceramide induces MMP-9 expression through JAK2/STAT3 pathway in airway epithelium
by: Lingling Xuan, et al.
Published: (2020-08-01)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016-07-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
by: Yuhong Jiang, et al.
Published: (2021-04-01)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
by: Masayuki Takeda, et al.
Published: (2019-01-01)

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
by: Qing Tian, et al.
Published: (2011-09-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)